Neuroprotective drug to treat Acute Ischemic Stroke

Regulatory phase

Currently, Isquaemia Biotech is developing a new neuroprotective and antioxidant drug for acute ischemic stroke that improves the effectiveness of current treatments, the therapeutic window and meet unmet clinical needs.

The preclinical results obtained to date are very promising. Preliminary tests of toxicity, solubility, efficacy, toxicokinetics and metabolism have been successfully passed.

The success of the preclinical phase has allowed to enter to the regulatory phase and the favorable results of this phase will allow the company to enter the clinical phase and validate the treatment in patients undergoing thrombectomy.

The main objective is to continue its development, as it is a drug that will greatly improve the health sector and facilitate its licensing to the pharmaceutical industry.


Currently, Isquaemia Biotech has two candidate drugs for the treatment of acute ischemic stroke.

The second candidate drug has a different drug profile, but a similar mechanism of action. At present, this other compound represents a second treatment of the same pathology to expand the spectrum of possible treatments and ensure a long-life cycle of the company.

Moreover, Isquaemia is working on the use of its leading drug in other indications and pathological conditions such as Amyotrophic Lateral Sclerosis (ALS).

Read more: 

J. Med. Chem. 2019; 62:2184−2201

ACS Chem Neurosci. 2019; 10:2703-2706